scholarly journals Botulinum toxin type A and cervical dystonia: a seven-year follow-up

2011 ◽  
Vol 69 (5) ◽  
pp. 745-750 ◽  
Author(s):  
Carlos Henrique F. Camargo ◽  
Hélio Afonso G. Teive ◽  
Nilson Becker ◽  
Renato P. Munhoz ◽  
Lineu César Werneck
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Clinical Severity ◽  
Term Therapy ◽  
Regular Treatment

Most cases of cervical dystonia (CD) are idiopathic, and focal injections of botulinum toxin A (BoNT/A) are the treatment of choice. The objective of our study was to document the effects of long-term BoNT/A treatment in idiopathic CD patients. Fifty-eight patients with idiopathic CD were recruited from March 2001 to May 2002. Twenty-eight of the subjects were available for reassessment after seven years. During this period, all had received regular treatment with BoNT/A injections. Clinical information about patients and the severity of CD (TWSTRS and VAPS) at baseline assessment (2001-2002) and follow-up (2008-2009) was compared. Significant motor improvement was detected based on TWSTRS scale scores, which were used to analyze clinical severity (19.6±6.6 and 17.7±4.8; p<0.05). There was no improvement in the severity of cervical pain (p=0.43). In conclusion, BoNT/A was a safe and effective long-term therapy for CD.

Lingual Dystonia Treated with Botulinum Toxin - A Case Report

1970 ◽  
Vol 24 (2) ◽  
pp. 75-78
Author(s):  
MA Hayee ◽  
QD Mohammad ◽  
H Rahman ◽  
M Hakim ◽  
SM Kibria
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
X Ray ◽  
Medical College ◽  
Lingual Dystonia ◽  
History Of ◽  
Chest X Ray

A 42-year-old female presented in Neurology Department of Sir Salimullah Medical College with gradually worsening difficulty in talking and eating for the last four months. Examination revealed dystonic tongue, macerated lips due to continuous drooling of saliva and aspirated lungs. She had no history of taking antiparkinsonian, neuroleptics or any other drugs causing dystonia. Chest X-ray revealed aspiration pneumonia corrected later by antibiotics. She was treated with botulinum toxin type-A. Twenty units of toxin was injected in six sites of the tongue. The dystonic tongue became normal by 24 hours. Subsequent 16 weeks follow up showed very good result and the patient now can talk and eat normally. (J Bangladesh Coll Phys Surg 2006; 24: 75-78)

scholarly journals Botulinum toxin A in the treatment of blepharospasm: a 10-year experience

2005 ◽  
Vol 63 (2a) ◽  
pp. 221-224 ◽  
Author(s):  
Laura Silveira-Moriyama ◽  
Lilian R. Gonçalves ◽  
Hsin Fen Chien ◽  
Egberto R. Barbosa
Keyword(s):  
Botulinum Toxin ◽  
Adverse Effects ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Term Effect ◽  
Secondary Resistance ◽  
School Of Medicine ◽  
Long Term Effect

To evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment of blepharospasm, a retrospective analysis was conducted from the patients seen at the Movement Disorders Clinic of the Department of Neurology, Hospital das Clínicas, University of São Paulo School of Medicine from 1993 to 2003. A total of 379 treatments with BTX were administered to 30 patients with blepharospasm. Sixty six per cent of the subjects had used oral medication for dystonia and only 15% of them reported satisfactory response to this treatment. Ninety three per cent of the patients showed significant improvement after the first BTX injection. There was no decrement in response when compared the first and the last injection recorded. Adverse effects, mostly minor, developed at least once in 53% of patients. Six patients (20%) discontinued the treatment but there was no case of secondary resistance.

1.254 Long-term follow-up of cervical dystonia patients treated with Botulinum toxin A

2007 ◽  
Vol 13 ◽  
pp. S66
Author(s):  
K. Kollewe ◽  
N. Buhr ◽  
K. Krampfl ◽  
R. Dengler ◽  
B. Mohammadi
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Long Term Follow Up

Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients

2001 ◽  
Vol 145 (2) ◽  
pp. 289-293 ◽  
Author(s):  
P. Schnider ◽  
E. Moraru ◽  
H. Kittler ◽  
M. Binder ◽  
G. Kranz ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Long Term Follow Up ◽  
Focal Hyperhidrosis

Long-term follow-up of cervical dystonia patients treated with botulinum toxin A

2003 ◽  
Vol 19 (3) ◽  
pp. 303-308 ◽  
Author(s):  
Peter Haussermann ◽  
Stefanie Marczoch ◽  
Christiane Klinger ◽  
Michael Landgrebe ◽  
Bastian Conrad ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Cervical Dystonia ◽  
Botulinum Toxin A ◽  
Toxin A ◽  
Long Term Follow Up

scholarly journals Randomized controlled study comparing clinical outcomes after injection botulinum toxin type A versus corticosteroids in chronic plantar fasciitis

2018 ◽  
Vol 4 (4) ◽  
pp. 672 ◽  
Author(s):  
Prakash D. Samant ◽  
Sachin Y. Kale ◽  
Sohrab Ahmed ◽  
Adnan Asif ◽  
Mahendra Fefar ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Clinical Outcomes ◽  
Plantar Fasciitis ◽  
Botulinum Toxin A ◽  
Botulinum Toxin Type A ◽  
Plantar Fascia ◽  
Botulinum Toxin Type ◽  
Toxin A ◽  
Pain Scores

<p class="abstract"><strong>Background:</strong> The plantar fascia is a common condition, for which there is no consensus on the best treatment option. The aim of this study is to compare the pain and fascia thickness outcomes of patients treated with botulinum toxin A injection versus corticosteroids injection.</p><p class="abstract"><strong>Methods:</strong> 50 patients of plantar fasciitis randomly received injections of either botulinum toxin A (100 units in 2.5 ml normal saline) or methylprednisolone (2 ml of 40 mg/ml) under ultrasonographic guidance. Patients were assessed for pain using the visual analogue scale (VAS) and fascia thickness at baseline, 1 and 3 week, 3, 6 and 12 months post injection. Patients in the two treatment groups were compared for pain scores and thickness at each follow up.<strong></strong></p><p class="abstract"><strong>Results:</strong> There were no significant differences in the patients in both the groups at baseline. Patients in both the groups had significant improvement in VAS pain scores over a 12 months follow- up. At the end of the study (12 month follow up), the VAS pain score was significantly lower in the group of patients who received botulinum toxin A (1.68±0.62 vs. 4.72±1.02, p value=0.001). There was a significantly less plantar fascia thickness in the group of patients who received botulinum toxin as compared to those who received corticosteroids at the 3 week, 3 month, 6 month and 1 year follow up.</p><p class="abstract"><strong>Conclusions:</strong> Better clinical outcomes were observed with botulinum toxin type A as compared to corticosteroids. Similar studies need to be replicated with larger sample sizes before this can be offered as a standard treatment for plantar fasciitis patients.</p>

CONDUCTING COMPARATIVE CLINICAL-PHARMACOLOGICAL EVALUATION PHARMACOTHERAPY PREPARATIONS OF BOTULINUM TOXIN A IN CHILDREN WITH CEREBRAL PALSY SYNDROME WITH MARKED SPASTICITY

2019 ◽  
Vol 25 (5-6) ◽  
pp. 293-302
Author(s):  
Anna Petrovna Solovieva ◽  
Vladimir Vladimirovich Arkhipov ◽  
Dmitry Vladimirovich Goryachev
Keyword(s):  
Cerebral Palsy ◽  
Botulinum Toxin ◽  
Botulinum Toxin A ◽  
Pharmacoeconomic Analysis ◽  
Botulinum Toxin Type A ◽  
Botulinum Toxin Type ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Clinical Pharmacological Evaluation

The original methodology for retrospective clinical studies on the criteria of “efficiency/safety” and pharmacoeconomics on the criteria of “cost/effectiveness”is proposed. The results of a retrospective study of medical records in 169 patients with cerebral palsy, which showed that the use of drugs botulinum toxin type A is an important integral component in the long-term treatment of children with spastic forms of cerebral palsy. Presents the results of pharmacoeconomic analysis of the treatment of the syndrome of spasticity in cerebral palsy when used in the complex treatment of Dysport, Botox and Xeomin.

Sign in / Sign up

Export Citation Format

Share Document